HR deficiency might predict therapy responsiveness beyond BRCA1/2 mutations; in a recently published phase II trial patients with metastatic prostate cancer and aberrations in DNA repair genes including BRCA1/2, ATM, FA genes and CHEK2 had a highly significantly increased therapeutic response to the PARP inhibitor olaparib compared to patients without such mutations [27]. The gene discussed is PARP1; the disease is metastatic prostate carcinoma.